[The polychemotherapy and combined treatment of patients with stage-I and -II lymphogranulomatosis and unfavorable prognosis].
As many as 104 patients with lymphogranulomatosis, clinical stages I-II, having an unfavourable prognosis were examined for the efficacy of polychemotherapy and combined treatment. Polychemotherapy was received by 47 patients, combined treatment (chemo- plus radiotherapy) by 57 patients. Complete remissions were attained significantly more often in patients given combined treatment (92%) as compared to patients on polychemotherapy alone (64%). After complete remissions relapses occurred in 60% of the patients on polychemotherapy and in 13% of the patients receiving combined treatment. The 7-year survival without any relapses was significantly higher (85%) in patients on combined therapy as compared to patients given polychemotherapy (36%). However, the 10-year survival appeared the same in both the groups (87 and 88%). Splenectomy affected neither the rate of relapses in both the groups nor the immediate treatment efficacy or survival.
Demina
E A
EA
Kaverzneva
M M
MM
Kondrat'eva
N F
NF
Agafonov
V A
VA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D015182:Lymphatic Irradiation; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction; D013156:Splenectomy; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use
D011344:Procarbazine; D014747:Vinblastine; D003520:Cyclophosphamide; D011239:Prednisolone
Polikhimioterapiia i kombinirovannoe lechenie bol'nykh limfogranulematozom I--II stadiĭ pri neblagopriiatnom prognoze.